Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reply to ‘Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting’

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Carroll PR, Parsons JK, Andriole G, et al. NCCN clinical practice guidelines in oncology (NCCN guidelines): prostate cancer early detection, version 2. 2017. www.nccn.org.

  2. 2.

    Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185:1650–5.

    CAS  Article  Google Scholar 

  3. 3.

    Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015;68:464–70.

    Article  Google Scholar 

  4. 4.

    White J, Shenoy BV, Tutrone RF, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer Prostatic Dis. 2018;21:78–84.

    Article  Google Scholar 

Download references

Funding

This work was supported in part by funds from the Sidney Kimmel Center for Prostate and Urologic Cancers, a Specialized Programs of Research Excellence grant (P50-CA92629) from the National Cancer Institute to Dr. Howard Scher, and a National Institutes of Health/National Cancer Institute Cancer Center Support Grant (P30-CA008748) to Memorial Sloan Kettering Cancer Center, a grant from the National Cancer Institute as part of the Cancer Intervention and Surveillance Modeling Network (U01CA199338-02), and the David H. Koch prostate cancer research fund.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Behfar Ehdaie.

Ethics declarations

Conflict of interest

SC has received a lecture fee and travel support from Astellas unrelated to this letter. The sponsor had no role in the writing of this letter, in the analysis or interpretation of data, and in the decision to publish the letter.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ehdaie, B., Carlsson, S. Reply to ‘Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting’. Prostate Cancer Prostatic Dis 21, 446–447 (2018). https://doi.org/10.1038/s41391-018-0052-y

Download citation

Further reading

Search

Quick links